JP7636812B2 - 創傷治癒を促進するための組成物および方法 - Google Patents

創傷治癒を促進するための組成物および方法 Download PDF

Info

Publication number
JP7636812B2
JP7636812B2 JP2022506461A JP2022506461A JP7636812B2 JP 7636812 B2 JP7636812 B2 JP 7636812B2 JP 2022506461 A JP2022506461 A JP 2022506461A JP 2022506461 A JP2022506461 A JP 2022506461A JP 7636812 B2 JP7636812 B2 JP 7636812B2
Authority
JP
Japan
Prior art keywords
peptide
enos
ccr10
myr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543056A (ja
JP2022543056A5 (enExample
Inventor
ミンシャル，リチャード，ディー．
チェン，ジェンロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2022543056A publication Critical patent/JP2022543056A/ja
Publication of JP2022543056A5 publication Critical patent/JP2022543056A5/ja
Application granted granted Critical
Publication of JP7636812B2 publication Critical patent/JP7636812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022506461A 2019-07-29 2020-07-28 創傷治癒を促進するための組成物および方法 Active JP7636812B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879717P 2019-07-29 2019-07-29
US62/879,717 2019-07-29
PCT/US2020/043813 WO2021021774A1 (en) 2019-07-29 2020-07-28 Composition and method for promoting wound healing

Publications (3)

Publication Number Publication Date
JP2022543056A JP2022543056A (ja) 2022-10-07
JP2022543056A5 JP2022543056A5 (enExample) 2023-07-31
JP7636812B2 true JP7636812B2 (ja) 2025-02-27

Family

ID=72047146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506461A Active JP7636812B2 (ja) 2019-07-29 2020-07-28 創傷治癒を促進するための組成物および方法

Country Status (7)

Country Link
US (1) US20220265759A1 (enExample)
EP (1) EP4003393A1 (enExample)
JP (1) JP7636812B2 (enExample)
KR (1) KR20220042200A (enExample)
CA (1) CA3148980A1 (enExample)
MX (1) MX2022001020A (enExample)
WO (1) WO2021021774A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121305B (zh) * 2023-01-03 2024-11-22 广州医科大学附属第五医院 间充质干细胞在糖尿病相关疾病中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537251A (ja) 1998-11-06 2004-12-16 セント ビンセンツ インスチチュート オブ メディカル リサーチ 安全ロープ用アンカー
WO2009012435A1 (en) 2007-07-19 2009-01-22 The Trustees Of The University Of Pennsylvania Conformational entropy in molecular recognition
JP2009538915A (ja) 2006-05-31 2009-11-12 ベス イスラエル ディーコネス メディカル センター 妊娠の合併症を診断および治療する方法
WO2011062155A1 (ja) 2009-11-19 2011-05-26 タカラバイオ株式会社 変異型Ｇａｇタンパク質をコードする核酸

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPS6229997A (ja) 1985-04-08 1987-02-07 Sankyo Co Ltd Ｃ末端にプロリンアミドを有するペプチドの製法
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5580751A (en) 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
WO1993002697A1 (en) 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US5709878A (en) 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
EP1553973A4 (en) * 2002-08-16 2006-03-01 Schering Ag MUTANTS OF ENOS USEFUL FOR GENE THERAPY
ES2637956T3 (es) 2003-01-24 2017-10-18 Stiefel Research Australia Pty Ltd Espuma farmacéutica
AU2006259408A1 (en) 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537251A (ja) 1998-11-06 2004-12-16 セント ビンセンツ インスチチュート オブ メディカル リサーチ 安全ロープ用アンカー
JP2009538915A (ja) 2006-05-31 2009-11-12 ベス イスラエル ディーコネス メディカル センター 妊娠の合併症を診断および治療する方法
WO2009012435A1 (en) 2007-07-19 2009-01-22 The Trustees Of The University Of Pennsylvania Conformational entropy in molecular recognition
WO2011062155A1 (ja) 2009-11-19 2011-05-26 タカラバイオ株式会社 変異型Ｇａｇタンパク質をコードする核酸

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIAZZA, M. et al，Solution Structure of Calmodulin Bound to the Target Peptide of Endothelial Nitric Oxide Synthase Phosphorylated at Thr495，Biochemistry，2014年，Vol.53，pp.1241-1249
PIAZZA, M. et al，Structual Studies of a Complex Between Endothelial Nitric Oxide Synthase and Calmodulin at Physiological Calcium Concentration，Biochemistry，2016年，Vol.55，pp.5962-5971

Also Published As

Publication number Publication date
EP4003393A1 (en) 2022-06-01
WO2021021774A1 (en) 2021-02-04
MX2022001020A (es) 2022-04-06
CA3148980A1 (en) 2021-02-04
KR20220042200A (ko) 2022-04-04
JP2022543056A (ja) 2022-10-07
US20220265759A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US7429567B2 (en) Sustained delivery of PDGF using self-assembling peptide nanofibers
EP2076290B1 (en) Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US7659252B2 (en) Transdermal delivery peptides and method of use thereof
JP2011506446A (ja) 損傷した創傷治癒組成物および治療
EP2310041B1 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
JP7269649B2 (ja) Ｋｉｆ１３ｂ由来ペプチドおよび血管新生阻害方法
JP2013536158A (ja) 創傷治癒のための新規ペプチド
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
JP7636812B2 (ja) 創傷治癒を促進するための組成物および方法
JP2022502359A (ja) 皮膚科障害の処置のための薬剤
US10835538B2 (en) Method of treating benign prostatic hyperlasia with antibiotics
AU2005222085B2 (en) Treating or preventing extracellular matrix build-up
KR20220079651A (ko) 진통 및 마취 펩티드 및 기타 제제
RU2820132C2 (ru) Способ улучшения симптомов со стороны нижних мочевыводящих путей
RU2780890C2 (ru) Способ лечения доброкачественной гиперплазии предстательной железы с помощью антибиотиков
JP2025526398A (ja) 末梢血管疾患を治療するための組成物及び方法
KR20220008303A (ko) 하부 요로 증상의 개선 방법
US6221855B1 (en) Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250206

R150 Certificate of patent or registration of utility model

Ref document number: 7636812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150